Induction of rat intestinal P-glycoprotein by spironolactone and its effect on absorption of orally administered digoxin

Journal of Pharmacology and Experimental Therapeutics

Volumn 318, Issue 3, 2006, Pages 1146-1152

  Ghanem, Carolina I ^a   Gómez, Paula C ^a   Arana, María C ^a   Perassolo, María ^a   Carpini, Griselda Delli ^a   Luquita, Marcelo G ^b   Veggi, Luis M ^b   Catania, Viviana A ^b   Bengochea, Laura A ^a   Mottino, Aldo D ^b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

DIGOXIN; GLYCOPROTEIN P; RHODAMINE 123; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRUSH BORDER; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; IMMUNOFLUORESCENCE MICROSCOPY; IN VIVO STUDY; INTESTINE ABSORPTION; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TRANSPORT; RAT; SEROSA; SMALL INTESTINE MUCOSA; UPREGULATION; URINARY EXCRETION; WESTERN BLOTTING;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL TRANSPORT; DIGOXIN; DRUG INTERACTIONS; INTESTINAL ABSORPTION; INTESTINES; MALE; P-GLYCOPROTEIN; RATS; RATS, WISTAR; SPIRONOLACTONE;

EID: 33747618957     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.105668     Document Type: Article

References (39)

1. Alqawi O, Bates S, and Georges E (2004) Arginine482 to threonine mutation in the breast cancer resistance protein ABCG2 inhibits rhodamine 123 transport while increasing binding. Biochem J 382:711-716.
2. Buck SH and Lage GL (1971) Possible mechanism of the prevention of digitoxin toxicity by spironolactone in the mouse. Arch Int Pharmacodyn Ther 189:192-197.
3. Catania VA, Luquita MG, Sánchez Pozzi EJ, Ikushiro S, Emi Y, Iyanagi T, and Mottino AD (2003) Effect of spironolactone on the expression of rat hepatic UDPglucuronosyltransferase. Biochem Pharmacol 66:171-177.
4. Catania VA, Luquita MG, Sánchez Pozzi EJ, and Mottino AD (1998) Enhancement of intestinal UDP-glucuronosyltransferase activity in partially hepatectomized rats. Biochim Biophys Acta 1380:345-353.
5. Doherty MM and Charman WN (2002) The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism? Clin Pharmacokinet 41:235-253.
6. Drescher S, Glaeser H, Murdter T, Hitzl M, Eichelbaum M, and Fromm MF (2003) P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 73:223-231.
7. Eberhart D, Fitzgerald K, and Parkinson A (1992) Evidence for the involvement of a distinct form of cytochrome P450 3A in the oxidation of digitoxin by rat liver microsomes. J Biochem Toxicol 7:53-64.
8. Efferth T, Lohrke H, and Volm M (1989) Reciprocal correlation between expression of P-glycoprotein and accumulation of rhodamine 123 in human tumors. Anticancer Res 9:1633-1637.
9. Feller DR and Gerald MC (1971a) Interactions of spironolactone with hepatic microsomal drug-metabolizing enzyme systems. Biochem Pharmacol 20:1991-2000.
10. Feller DR and Gerald MC (1971b) Stimulation of liver microsomal drug metabolism in male and female mice by spironolactone and aldadiene. Proc Soc Exp Biol Med 136:1347-1350.
11. Fromm MF (2003) Importance of P-glycoprotein for drug disposition in humans. Eur J Clin Investig 33 (Suppl 2):6-9.
12. Fromm MF, Kim RB, Stein CM, Wilkinson GR, and Roden DM (1999) Inhibition of P-glycoprotein-mediated drug transport: a unifying mechanism to explain the interaction between digoxin and quinidine [see comments]. Circulation 99:552-557.
13. Ghanem CI, Gomez PC, Arana MC, Perassolo M, Ruiz ML, Villanueva SS, Ochoa EJ, Catania VA, Bengochea LA, and Mottino AD (2004) Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol 68:791-798.
14. Guo GL, Choudhuri S, and Klaassen CD (2002) Induction profile of rat organic anion transporting polypeptide 2 (oatp2) by prototypical drug-metabolizing enzyme inducers that activate gene expression through ligand-activated transcription factor pathways. J Pharmacol Exp Ther 300:206-212.
15. Hamrick ME, Zampaglione NG, Stripp B, and Gillette JR (1973) Investigation of the effects of methyltestosterone, cortisone and spironolactone on the hepatic microsomal mixed function oxidase system in male and female rats. Biochem Pharmacol 22:293-310.
16. Han Y and Sugiyama Y (2006) Expression and regulation of breast cancer resistance protein and multidrug resistance associated protein 2 in BALB/c mice. Biol Pharm Bull 29:1032-1035.
17. Lin JH and Yamazaki M (2003) Role of P-glycoprotein in pharmacokinetics: clinical implications. Clin Pharmacokinet 42:59-98.
18. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
19. Meier PJ, Sztul ES, Reuben A, and Boyer JL (1984) Structural and functional polarity of canalicular and basolateral plasma membrane vesicles isolated in high yield from rat liver. J Cell Biol 98:991-1000.
20. Miguet JP, Vuitton D, Thebault-Lucas A, Joanne C, and Dhumeaux D (1980) Spironolactone and enzyme induction in patients with alcoholic cirrhosis. Gastroenterology 78:996-1000.
21. Mottino AD, Guibert EE, and Rodríguez Garay EA (1989) Additive effect of combined spironolactone and phenobarbital treatment on hepatic bilirubin UDPglucuronyltransferase. Biochem Pharmacol 38:851-853.
22. Mottino AD, Hoffman T, Jennes L, and Vore M (2000) Expression and localization of multidrug resistant protein mrp2 in rat small intestine. J Pharmacol Exp Ther 293:717-723.
23. Nakamura T, Kakumoto M, Yamashita K, Takara K, Tanigawara Y, Sakaeda T, and Okumura K (2001) Factors influencing the prediction of steady state concentrations of digoxin. Biol Pharm Bull 24:403-408.
24. Ochs HR, Greenblatt DJ, Bodem G, and Smith TW (1978) Spironolactone. Am Heart J 96:389-400.
25. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, and Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341:709-717.
26. 3H-digitoxin in the rat. Biochem Pharmacol 23:2567-2575.
27. Ruiz ML, Villanueva SS, Luquita MG, Sanchez-Pozzi EJ, Crocenzi FA, Pellegrino JM, Ochoa JE, Vore M, Mottino AD, and Catania VA (2005) Mechanisms involved in spironolactone-induced choleresis in the rat. Role of multidrug resistance-associated protein 2. Biochem Pharmacol 69:531-539.
28. Schuetz EG, Beck WT, and Schuetz JD (1996) Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol 49:311-318.
29. Schuetz EG, Brimer C, and Schuetz JD (1998) Environmental xenobiotics and the antihormones cyproterone acetate and spironolactone use the nuclear hormone pregnenolone X receptor to activate the CYP3A23 hormone response element. Mol Pharmacol 54:1113-1117.
30. Selye H, Krajny M, and Savoie L (1969) Digitoxin poisoning: prevention by spironolactone. Science (Wash DC) 164:842-843.
31. Solymoss B, Toth S, Varga S, and Selye H (1971) Protection by spironolactone and oxandrolone against chronic digitoxin or indomethacin intoxication. Toxicol Appl Pharmacol 18:586-592.
32. Stripp B, Hamrick ME, Zampaglione NG, and Gillette JR (1971) The effect of spironolactone on drug metabolism by hepatic microsomes. J Pharmacol Exp Ther 176:766-771.
33. Sun J, He ZG, Cheng G, Wang SJ, Hao XH, and Zou MJ (2004) Multidrug resistance P-glycoprotein: crucial significance in drug disposition and interaction. Med Sci Monit 10:RA5-14.
34. Takano M, Yumoto R, and Murakami T (2006) Expression and function of efflux drug transporters in the intestine. Pharmacol Ther 109:137-161.
35. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, and Okumura K (2002) Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci 70:1491-1500.
36. Verschraagen M, Koks CH, Schellens JH, and Beijnen JH (1999) P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol Res 40:301-306.
37. Vohringer HF and Rietbrock N (1974) Metabolism and excretion of digitoxin in man. Clin Pharmacol Ther 16:796-806.
38. Wirth KE, Frolich JC, Hollifield JW, Falkner FC, Sweetman BS, and Oates JA (1976) Metabolism of digitoxin in man and its modification by spironolactone. Eur J Clin Pharmacol 09:345-354.
39. Zhang Y, Gupta A, Wang H, Zhou L, Vethanayagam RR, Unadkat JD, and Mao Q (2005) BCRP transports dipyridamole and is inhibited by calcium channel blockers. Pharm Res (NY) 22:2023-2034.